Skip to main content Skip to main content
Go to homepage

Apixaban to Prevent Blood Clots in Children With Leukemia

Apixaban for Prevention of Blood Clots in Children With Leukemia


The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy; including Pegylated L-Asparaginase and have a central line (a catheter inserted for administration of medications and blood sampling).

Complete study information:

Who May Qualify?:
  • Patients with a new diagnosis of de novo ALL, lymphomas (T or B cell), or mixed-phenotype acute leukemia
  • Patients with a functioning Central Venous Access Device ( i.v. bag used to administer drugs through the vein)
  • Patients who are able to tolerate oral medication or have it administered via an Nasogastric tube (NGT) or GT tube
  • Males and females, age 1 year (365 days) to < 18 (17 years and 364 days) years.
  • Patients with platelet Counts ≥ 20000/microL
Who Does Not Qualify:


  • Scheduled to have > 3 Lumbar Punctures over the course of the treatment period ( often known to the public as “spinals”)
  • With prior history of documented DVT or PE in the past 3 months
  • With known inherited bleeding disorder or clotting disorder.
  • Who have had major surgery [excluding Central Venous Access Device (CVAD) replacement and bone marrow aspiration and non-open biopsy] within the last 7 days prior to enrollment that may be associated with a risk of bleeding. Open biopsy is considered a major surgery.
  • With uncontrolled severe hypertension at enrollment (high blood pressure). Severe hypertension is defined as a systolic or diastolic blood pressure (BP) > 5 mm Hg above the 95th percentile as defined by the National High Blood Pressure Education Program Working Group (NHBPEP) established guidelines for the definition of normal and elevated blood pressure in children
  • With extreme hyper leukocytosis, white blood cell (WBC) counts over 200 x 109/L (200,000/microL) at the time of enrollment
  • With liver disease or liver dysfunction.
  • With history of significant adverse reaction or major bleeding related adverse reaction to other anticoagulant or antiplatelet agents
  • With history of any significant drug allergy. Any investigational drug being administered during the study
Study Status:
Study Sponsor:

Bristol Myers - Squibb

Full IRB Study Title:
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Pegylated (PEG) L-Asparaginase
IRB Study ID:
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email
Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research, Shannon E. Wilkes Targeted Therapy Program; The Jeffrey A. Barbour Chair for Pediatric Hematology/Oncology Research and Healing; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.